May 27 (Reuters) - Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV , saying the purchase underscored its commitment to buy Mylan as soon as possible.
growth prospects, we still think Par appears considerably disadvantaged, even following a combination with Endo (Peers such as Teva , Mylan, Dr. Reddy’s, and Hikma are more vertically integrated and run lower cost operations). Endo's management has
May 7 (Reuters) - California's highest court on Thursday revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of...
May 7 (Reuters) - California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's...
challenges. Mylan remains persistent in its pursuit of Perrigo, but we still think the situation remains highly uncertain thanks to Teva ’s own offer $82 per share (50% cash/50% stock) for Mylan. As we have previously stated, we think Perrigo’s over
We've adjusted our revenue and profit forecast for the company as the sole generic approval for the time being, but with Teva ’s ability to continually shift more patients into a new three-times-per-week formulation until our estimate of a generic
* Teva shares down 1.2 pct in New York (Adds comments on Mylan, Copaxone, analyst, shares)
* Confident in our ability to defend patent on 40 mg Copaxone Further company coverage: (Reporting By Steven Scheer and Tova Cohen)
April 30 (Reuters) - Teva Pharmaceutical Industries TEVA .N> CEO Erez Vigodman says:
TEL AVIV, April 30 (Reuters) - Teva Pharmaceutical Industries , which is seeking to acquire rival Mylan Inc for over $40 billion, posted higher first quarter net profit that beat analysts' estimates and raised its full year outlook.